Multiplex Assay Kit for Insulin Like Growth Factor Binding Protein 7 (IGFBP7) ,etc. by FLIA (Flow Luminescence Immunoassay)

FSTL2; IGFBP-7v; MAC25; PSF; TAF; IGFBP-rP1; MAC25 protein; Prostacyclin-stimulating factor; PGI2-stimulating factor; Tumor-derived adhesion factor

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Insulin Like Growth Factor Binding Protein 7 (IGFBP7) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Insulin Like Growth Factor Binding Protein 7 (IGFBP7) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Insulin Like Growth Factor Binding Protein 7 (IGFBP7) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Insulin Like Growth Factor Binding Protein 7 (IGFBP7) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 82-93 90
EDTA plasma(n=5) 96-105 101
heparin plasma(n=5) 98-105 102

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Insulin Like Growth Factor Binding Protein 7 (IGFBP7) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Insulin Like Growth Factor Binding Protein 7 (IGFBP7) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Insulin Like Growth Factor Binding Protein 7 (IGFBP7) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 79-90% 99-105% 81-102% 85-98%
EDTA plasma(n=5) 85-94% 87-95% 79-103% 79-103%
heparin plasma(n=5) 79-102% 88-101% 81-102% 92-102%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:IGFBP7) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
PLoS One Role of IGFBP7 in Diabetic Nephropathy: TGF-β1 Induces IGFBP7 via Smad2/4 in Human Renal Proximal Tubular Epithelial Cells Pubmed:26974954
PLOS ONE Role of IGFBP7 in Diabetic Nephropathy: TGF-β1 Induces IGFBP7 via Smad2/4 in Human Renal Proximal Tubular Epithelial Cells. pubmed:26974954
Journal of Alzheimers Disease Urine-Based Biomarkers for Alzheimer's Disease Identified Through Coupling Computational and Experimental Methods Pubmed:30040720
Cancers (Basel). IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung Cancer Pubmed: 30609749
Advances in Medical Sciences Insulin-like growth factor-binding protein 7 (IGFBP 7) as a new biomarker in coronary heart disease Pubmed: 30769262
PLoS One Altered insulin-like growth factor-2 signaling is associated with psychopathology and cognitive deficits in patients with schizophrenia Pubmed: 32191705
Scientific reports Discovery of novel biomarkers for atherosclerotic aortic aneurysm through proteomics-based assessment of disease progression Pubmed: 32286426
Genet Med SNORD116 and growth hormone therapy impact IGFBP7 in Prader¨CWilli syndrome 34040195
Sci Rep Biomarkers of persistent renal vulnerability after acute kidney injury recovery 34707157
Biomolecules IGFBP7 Concentration May Reflect Subclinical Myocardial Damage and Kidney Function in Patients with Stable Ischemic Heart Disease Pubmed:35204773
Biomolecules Insulin-Like Growth Factor-Binding Protein 7 (IGFBP-7)—New Diagnostic and Prognostic Marker in Symptomatic Peripheral Arterial Disease?—Pilot Study Pubmed:35625639
Catalog No. Related products for research use of Rattus norvegicus (Rat) Organism species Applications (RESEARCH USE ONLY!)
RPB673Ra01 Recombinant Insulin Like Growth Factor Binding Protein 7 (IGFBP7) Positive Control; Immunogen; SDS-PAGE; WB.
PAB673Ra01 Polyclonal Antibody to Insulin Like Growth Factor Binding Protein 7 (IGFBP7) WB; IHC; ICC; IP.
MAB673Ra21 Monoclonal Antibody to Insulin Like Growth Factor Binding Protein 7 (IGFBP7) WB; IHC; ICC; IP.
SEB673Ra ELISA Kit for Insulin Like Growth Factor Binding Protein 7 (IGFBP7) Enzyme-linked immunosorbent assay for Antigen Detection.
LMB673Ra Multiplex Assay Kit for Insulin Like Growth Factor Binding Protein 7 (IGFBP7) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.